Published in J Clin Oncol on February 01, 1985
Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol (2009) 1.21
Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int (2014) 1.18
WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. J Assoc Res Otolaryngol (2004) 1.02
Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS One (2013) 0.98
Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication. World J Nephrol (2012) 0.86
Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin. Br J Cancer (2002) 0.79
A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. Br J Cancer (1993) 0.75
Glutathione restores normal cell activation and cell cycle progression in cis-platinum treated human lymphocytes. Br J Cancer (1991) 0.75
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA (1998) 5.09
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 4.90
Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem (2000) 3.12
Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. Mol Cell Biol (1998) 3.09
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med (2001) 2.47
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Tumor chemosensitivity and chemoresistance assays. Cancer (1996) 2.14
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst (1997) 1.88
Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc) (2005) 1.85
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol (2001) 1.61
Control of electron flux through the respiratory chain in mitochondria and cells. Biol Rev Camb Philos Soc (1987) 1.60
Selective targeting of an antioxidant to mitochondria. Eur J Biochem (1999) 1.58
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
Endogenous complement C3 synthesis in immune complex nephritis. Lancet (1993) 1.57
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol (1996) 1.57
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem (1984) 1.54
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
Quantitation and origin of the mitochondrial membrane potential in human cells lacking mitochondrial DNA. Eur J Biochem (1999) 1.51
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Chiropractic in The Netherlands: a survey of Dutch chiropractors. J Manipulative Physiol Ther (1995) 1.48
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Chiropractic patients in the Netherlands: a descriptive study. J Manipulative Physiol Ther (2000) 1.47
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma. Obstet Gynecol (1988) 1.45
Circulating immunoglobulin complexes in Wegener's granulomatosis. Am J Med (1976) 1.43
Cell-free assays for gamma-secretase activity. FASEB J (2000) 1.41
Autogenous patching of a kinked internal carotid artery. Surgery (1998) 1.39
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging (2001) 1.39
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
Changes in mitochondrial membrane potential during staurosporine-induced apoptosis in Jurkat cells. FEBS Lett (2000) 1.35
Prophylactic photopheresis and effect on graft atherosclerosis in cardiac transplantation. Transplant Proc (1995) 1.32
Disulphide formation on mitochondrial protein thiols. Biochem Soc Trans (2005) 1.31
Measurements of protein carbonyls, ortho- and meta-tyrosine and oxidative phosphorylation complex activity in mitochondria from young and old rats. Free Radic Biol Med (2001) 1.30
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc (1990) 1.25
Altered mitochondrial function in fibroblasts containing MELAS or MERRF mitochondrial DNA mutations. Biochem J (1996) 1.24
Vancomycin-induced vasculitis. South Med J (1986) 1.24
Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf (2001) 1.24
Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res (2001) 1.23
Clinimetric evaluation of the Sinonasal Outcome Test-16. Student Research Award 1998. Otolaryngol Head Neck Surg (1999) 1.23
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer (2003) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Free proximal trisomy 21 without the Down syndrome. Clin Genet (1987) 1.19
Decreased ATP synthesis is phenotypically expressed during increased energy demand in fibroblasts containing mitochondrial tRNA mutations. Eur J Biochem (1999) 1.19
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol (1995) 1.18
Anti-peptide antibodies detect oncogene-related proteins in urine. Proc Natl Acad Sci U S A (1985) 1.18
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol (2009) 1.17
Tim18p, a new subunit of the TIM22 complex that mediates insertion of imported proteins into the yeast mitochondrial inner membrane. Mol Cell Biol (2000) 1.17
Cancer incidence in the industrial corridor: an update. J La State Med Soc (1998) 1.17
Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol (1987) 1.17
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Totally implantable system for peritoneal access. J Clin Oncol (1984) 1.15
Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene (2001) 1.15
Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion. Eur J Biochem (1998) 1.14
Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc (1997) 1.14
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
Androgens modulate beta-amyloid levels in male rat brain. J Neurochem (2003) 1.12
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol (1994) 1.11
Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol (1992) 1.11
Renal disease and use of topical non-steroidal anti-inflammatory drugs. BMJ (1994) 1.10
Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol (1994) 1.10
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
Outcome of transplantation of non-heart-beating donor kidneys. Lancet (1995) 1.09
Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol (1999) 1.08
The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol (1999) 1.07
Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer (1975) 1.07